Open an account

Tempest Therapeutics

TPST · NASDAQ

$0.5762−$0.0239 (−3.98%)TodayMarket closed ·
Prev close $0.6001

About TPST

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 4 full-time employees. The company went IPO on 2012-10-04. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Employees
4
Headquarters
Brisbane California, California
Listed
Oct 4, 2012
Sector
Health Care
Industry
Biotechnology
Website
tempesttx.com

TPST key statistics

Market cap
9.73M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
587.83K
Volume
144.97K
Open price
$0.6005
High today
$0.6281
Low today
$0.573
52 Week high
$11.13
52 Week low
$0.60

Tempest Therapeutics (TPST) at a glance

Tempest Therapeutics (TPST) last traded at $0.5762, with a market cap of 9.73M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.573 and $0.6281. The current price is 0.6% above the day's low and 8.3% below its high.

Volume so far is 144.97K shares, below the average of 587.83K shares a day.

Over the past year Tempest Therapeutics has ranged from $0.60 to $11.13, and now sits 0% of the way up that range.

Tempest Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.34 per share against an estimate of -$0.306.

The average analyst price target is $7.14, 1139.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $7.14
Low
$7.07
Now
$0.5762
High
$7.35

TPST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 26.6% on average.

  1. Q3 FY24: reported -$5.33 per share against an estimate of -$4.80
  2. Q4 FY24: reported -$4.03 per share against an estimate of -$3.34
  3. Q1 FY25: reported -$3.16 per share against an estimate of -$3.36
  4. Q2 FY25: reported -$2.07 per share against an estimate of -$2.66
  5. Q3 FY25: reported -$0.79 per share against an estimate of -$3.34
  6. Q4 FY25: reported -$0.62 per share against an estimate of -$0.6324
  7. Q1 FY26: reported -$2.53 per share against an estimate of -$0.2856
  8. Q2 FY26: reported -$0.34 per share against an estimate of -$0.306

TPST news

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Henry Khederian

    Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?

  • Press releaseGlobe Newswire

    Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

  • Press releaseGlobe Newswire

    Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

  • Avi Kapoor

    Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast

Similar companies

Companies in the same industry as Tempest Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.